SCHEMBL3567189

SCHEMBL3567189

COc1ccccc1-c1cn(S(=O)(=O)c2ccc(C)cc2)c2ncc(-c3cc[nH]n3)cc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.45
TSHR P16473 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
PTPN11 Q06124 1/20 0.43
BRD4 O60885 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
HTT P42858 2/20 0.37
LMNA P02545 2/20 0.37
MAPK1 P28482 1/20 0.37
ALDH1A1 P00352 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MAOB P27338 1/20 0.35
DRD2 P14416 2/20 0.34
HTR2A P28223 2/20 0.34
HTR7 P34969 2/20 0.34
HTR6 P50406 1/20 0.34
SCN9A Q15858 1/20 0.34
TRIM24 O15164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3571375 0.85 MAPT (0.51) MAPTTSHRSMN1; SMN2PTPN11BRD4
SCHEMBL12763220 0.85 TSHR (0.53) MAPTTSHRSMN1; SMN2PTPN11BRD4
SCHEMBL15805344 0.82 PTPN11 (0.45) MAPTTSHRSMN1; SMN2PTPN11BRD4
SCHEMBL16023217 0.82 PTPN11 (0.45) MAPTTSHRSMN1; SMN2PTPN11BRD4
SCHEMBL3568076 0.82 PTPN11 (0.47) MAPTTSHRSMN1; SMN2PTPN11BRD4
SCHEMBL13010696 0.82 TSHR (0.50) MAPTTSHRSMN1; SMN2PTPN11BRD4
SCHEMBL1516730 0.82 TSHR (0.50) MAPTTSHRSMN1; SMN2PTPN11BRD4
SCHEMBL1516591 0.82 TSHR (0.53) MAPTTSHRSMN1; SMN2PTPN11BRD4
SCHEMBL1517554 0.81 PTPN11 (0.44) MAPTTSHRSMN1; SMN2PTPN11BRD4
SCHEMBL1516738 0.81 TSHR (0.48) MAPTTSHRSMN1; SMN2PTPN11BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7709645-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2010-05-04 US disclosed
US-7709645-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2010-05-04 US disclosed
US-7709645-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2010-05-04 US disclosed
EP-2134343-A2 PYRROLO-PYRIDINE KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2009-12-23 EP disclosed
US-20090143352-A1 PYRROLO-PYRIDINE KINASE MODULATIORS SGX PHARMACEUTICALS, INC. (US) 2009-06-04 US disclosed
US-20090143352-A1 PYRROLO-PYRIDINE KINASE MODULATIORS SGX PHARMACEUTICALS, INC. (US) 2009-06-04 US disclosed
US-20090143352-A1 PYRROLO-PYRIDINE KINASE MODULATIORS SGX PHARMACEUTICALS, INC. (US) 2009-06-04 US disclosed
WO-2008124849-A2 PYRROLO-PYRIDINE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-16 WO disclosed
WO-2008124849-A2 PYRROLO-PYRIDINE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143352-A1 PYRROLO-PYRIDINE KINASE MODULATIORS MAP4K2, PDXK, MAP4K1 MAPT 1385/4885TSHR 3000/4885SMN1; SMN2 2843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.